Corona Vaccine

Here are three of the vaccine that are tested at the time

Moderna's mRNA-1273

Moderna Inc. of Cambridge, Massachusetts, has already begun Phase I human testing of its mRNA-1273 at Kaiser Permanente Washington Health Research Institute in Seattle. The test has enrolled 45 healthy adults ages 18 to 55. Phase I will continue over the next six weeks.

Phase I of testing looks at the vaccine's safety and whether it is producing an immune response. A later phase of research will look at whether the vaccine is effective in preventing infection.

Inovio's INO-4800

Inovio Pharmaceuticals of Plymouth Meeting, Pennsylvania, is using an approach similar to Moderna's to develop a vaccine by modelling off the virus' sequence. Three hours after China published the sequence of the virus online, Inovio developed INO-4800.

Inovio uses something called DNA medicine, which is made up of optimized DNA plasmids. Inovio has already developed a vaccine using this method for MERS, a different type of coronavirus. It is in Phase II of testing.

The company has begun preclinical testing of its COVID-19 vaccine in animals that have shown the desired immune response. It hopes to begin human trials in April starting with an introduction in 30 healthy people.

Regeneron's REGN3048-3051

Regeneron Pharmaceuticals of Tarrytown, New York, is working on an antibody treatment that uses the virus itself. The company genetically modifies mice to have human immune systems and then exposes them to part of the virus. The mice then build up antibodies to fight the virus.

Scientists have isolated the antibodies, as well as antibodies from humans who have recovered from COVID-19, and they will select the top two antibodies to create a cocktail that is injected in the patient. The two antibodies will target different parts of the virus and may help protect against multiple viral variants. In theory, that means the drug could still be effective if the virus mutates.

Source - Internet

this may be the product of copyright